Aliases:This biomarker is also known as:
TF, or transferrin, a glycoprotein with an approximate molecular weight of 76.5 kDa, is thought to have been created as a result of an ancient gene duplication event that led to generation of homologous C and N-terminal domains each of which binds one ion of ferric iron. The function of this protein is to transport iron from the intestine, reticuloendothelial system, and liver parenchymal cells to all proliferating cells in the body. This protein may also have a physiologic role as granulocyte/pollen-binding protein (GPBP) involved in the removal of certain organic matter and allergens from serum.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
In laboratory testing, transferrin, in a panel (including apolipoprotein A-1, transthyretin, and CA125) has been shown to be a highly sensitive (96%) predictor of early stage ovarian cancer and endometrial cancer.
Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. TF alone was not a strong predictor.
|QA State:||Under Review|
No additional prostate data available.
19 common probe sets (15 unique genes) were used to develop a PAM-based classifier, which had an average accuracy of 87% when it was tested on 47 independent tumor-adjacent stroma samples. The 15 genes represented in the classifier are: GADD45B, CDKN1A, NLRP1, ERBB3, FMO5, KIAA0746///SERINC2, AMFR, DPP4, PGC, YWHAE, EHF, TF, TNFSF10, EIF5A, TGM4. This is the first general tumor microenvironment-based prognostic classifier. Tumor-adjacent prostate cancer stroma contains numerous changes in gene expression at the time of diagnosis that correlate with the chance of relapse following prostatectomy. These results indicate that the prostate cancer microenvironment exhibits reproducible changes useful for predicting outcomes for patients.
- Diagnosis of prostate cancer using differentially expressed genes in stroma.
- A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
- Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
- Expression changes in the stroma of prostate cancer predict subsequent relapse.
- An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account.